Loading...

AVNS AVANOS MEDICAL INC Disposals and divestitures 8-K Filing

VNS

VNS

AVANOS MEDICAL INC

(AVNS)

2025 8-K

Management Changes

Earnings Results Report

Management Changes

Company Acquisition

Divestment of Assets

Financial Statements

Management Changes

CEO Appointment

CEO Appointment

Earnings Announcement

Investor Presentation

CFO Appointment

Management Changes

Results of Operations

Appointment of Director

Results of Operations

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Results of Operations and F...

Correction and Divestiture ...

Results of Operations

Share Repurchase Program

Investor Conferences

Entry into a Material Defin...

Results of Operations and A...

Appointment of Dr. Lisa Egb...

Financial Results Announcement

Amendment to Executive Seve...

Transformation Process

External Links:

On July 31, 2025, Avanos Medical, Inc. announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, LLC, and on August 1, 2025, appointed David Pacitti as a board member and Scott Galovan as CFO, offering Galovan a salary of $460,000 and equity awards valued at $500,000.

AI Assistant

AVANOS MEDICAL INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.